- Home
- XERS vs SGRY Comparison
XERS vs SGRY Comparison
Compare XERS & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | SGRY |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XERS | SGRY |
|---|---|---|
| Price | $13.32 | $23.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $12.86 | ★ $22.60 |
| AVG Volume (30 Days) | 2.2M | ★ 5.7M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 54.14 |
| EPS | ★ N/A | N/A |
| Revenue | $49,590,000.00 | ★ $1,145,438,000.00 |
| Revenue This Year | $32.91 | N/A |
| Revenue Next Year | $23.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $11.41 |
| 52 Week High | $11.42 | $23.38 |
Technical Indicators
Market Signals| Indicator | XERS | SGRY |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 85.12 |
| Support Level | $9.73 | $13.34 |
| Resistance Level | $10.60 | $23.38 |
| Average True Range (ATR) | 0.48 | 0.33 |
| MACD | -0.09 | 0.60 |
| Stochastic Oscillator | 39.36 | 97.53 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.